Description

Imfinzi (Durvalumab) is a type of immunotherapy drug used to treat certain forms of cancer, such as non-small cell lung cancer (NSCLC), biliary tract cancer, and hepatocellular carcinoma. For NSCLC, Imfinzi may be prescribed for patients whose cancer has not spread outside the chest, is not removable by surgery, and has either responded or stabilized following initial chemotherapy that includes platinum. It is classified as an immune checkpoint inhibitor drug, which helps the immune system recognize and attack cancer cells by blocking the programmed death-ligand 1 (PD-L1) pathway.

Directions

Imfinzi is typically administered as an intravenous infusion by a qualified healthcare professional. The recommended dosage for Imfinzi can vary based on the indication and whether it is used as a single agent or in combination with chemotherapy. Follow your healthcare provider's specific recommendations about the dosage and treatment schedule. Before receiving each infusion, your doctor may perform blood tests and evaluate your overall health to determine if you are fit for treatment.

Ingredients

The active ingredient in Imfinzi is Durvalumab. The Imfinzi injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution that is free from visible particles. In addition to Durvalumab, Imfinzi also contains several inactive ingredients that may support the formulation and packaging of the medication. These include L-histidine, L-histidine hydrochloride monohydrate, a,a-trehalose dihydrate, polysorbate 80, and water for injection.

Contraindications

The drug package insert does not list any contraindications for Imfinzi. However, patients who have had severe or life-threatening immune-mediated reactions to Durvalumab may need to avoid this medication.

Cautions

• Prior to initiating Imfinzi therapy, it is essential to inform your medical professional about:
• Any existing health issues, particularly those related to the immune or nervous systems.
• Whether you have undergone radiation treatment in the chest area or received an organ or stem cell transplant.
• Your pregnancy status or intention to become pregnant, as well as if you are currently breastfeeding.
• Imfinzi carries a risk of triggering severe immune-mediated reactions that may be life-threatening and can impact any body organ or system, including but not limited to pneumonitis, colitis, hepatitis, various endocrine disorders, skin issues, kidney problems, rejection of transplanted organs, and inflammation of the pancreas.
• Detecting adverse effects early is critical; therefore, tests to evaluate liver function, creatinine levels, and thyroid activity may be performed before and during the course of treatment.
• Therapeutic strategies may need to be adjusted, including pausing or stopping Durvalumab administration, due to immune-related adverse events.
• If an adverse reaction related to the infusion occurs, there may be a need to stop the infusion, decrease its rate, or halt the treatment altogether depending on how severe the reaction is.
• Patients who are either pre- or post-stem cell transplant may have an increased risk of severe complications, including death, when treated with PD-1/PD-L1 inhibitors such as Durvalumab.
• Durvalumab has the potential to harm an unborn child, and thus, women who could become pregnant should be aware of this hazard and instructed on the importance of using reliable birth control methods.

Side Effects

Imfinzi treatment can lead to various adverse effects. Common side effects of Imfinzi may include persistent cough, fatigue, inflammation of the lungs or complications following lung radiation, upper respiratory infections, skin rash, and shortness of breath.

Additionally, Imfinzi has the potential to trigger serious side effects, including respiratory conditions characterized by chronic cough and chest discomfort, severe stomach ache or presence of blood in stools, liver problems evident through skin and eye discoloration and dark-colored urine, hormonal irregularities causing headaches or mood changes, and kidney problems. Seek immediate healthcare assistance for any of these serious conditions or if symptoms related to infusion reactions such as skin flushing, fever, and skin rash occur.

References:

1. Imfinzi (Durvalumab) Imfinzi Package Insert. Wilmington, DE: AstraZeneca Pharmaceuticals; 2023.
2. Imfinzi (Durvalumab) Drug Label Information. Wilmington, DE: AstraZeneca Pharmaceuticals; 2023.

About Dr. Gerardo Sison (Page Author)

Dr. Sison graduated with honors from the University of Florida. He began his career in pharmacy counseling patients in a community setting and later served in hospitals and clinics. He has also worked in medication therapy management services. Read More....

Product Code : 14401